Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
Globe Newswire•20/10/2026•08:30 ET
0
Key Highlights
- ➤Optimi completed MDMA batch for Canadian Phase 3, Israel trial, and Australian commercial supply.
- ➤Canadian Phase 3 targets up to 100 veterans and frontline workers, beginning in 2027.
- ➤Australia MDMA export planned before end-2026 following received import permits.
- ➤Optimi MDMA capsules are commercially supplied in Australia under the Authorised Prescriber Scheme.
- ➤Health Canada has not authorized any Optimi MDMA drug products for market.
Expert Statements
Dane Stevens, Chief Executive Officer and Co-Founder of Optimi Health Corp.
“Veterans in Australia can already access MDMA-assisted therapy through their own government. Veterans in Canada cannot,”
Dane Stevens, Chief Executive Officer and Co-Founder of Optimi Health Corp.
“The Canadian Phase 3 trial is how we hope to close that gap, and the medicine for that trial is already made.”
Dane Stevens, Chief Executive Officer and Co-Founder of Optimi Health Corp.
“We are proud to supply MDMA commercially to clinics in Australia, and we are keeping a keen eye on the United States and other jurisdictions as access expands.”
Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers
Get started
Create a free account to read the full story.